Fifth Third Bancorp Decreases Position in Amgen Inc. $AMGN

Fifth Third Bancorp trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 1.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 293,372 shares of the medical research company’s stock after selling 4,986 shares during the period. Fifth Third Bancorp’s holdings in Amgen were worth $96,024,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. West Family Investments Inc. increased its position in shares of Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after purchasing an additional 30 shares in the last quarter. Viawealth LLC lifted its holdings in Amgen by 0.4% in the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after purchasing an additional 30 shares in the last quarter. LOM Asset Management Ltd lifted its holdings in Amgen by 1.2% in the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company’s stock valued at $721,000 after purchasing an additional 30 shares in the last quarter. Sittner & Nelson LLC boosted its stake in Amgen by 0.4% during the 3rd quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company’s stock worth $2,053,000 after purchasing an additional 30 shares during the last quarter. Finally, Smith Salley Wealth Management grew its holdings in shares of Amgen by 0.3% during the fourth quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company’s stock worth $3,530,000 after buying an additional 30 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Mizuho increased their target price on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Argus upped their price objective on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Freedom Capital downgraded shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. UBS Group raised their target price on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Finally, The Goldman Sachs Group boosted their target price on Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $356.62.

Amgen Trading Up 2.4%

Shares of AMGN stock opened at $346.25 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The company’s 50-day moving average price is $358.07 and its 200-day moving average price is $340.45. The stock has a market cap of $186.86 billion, a price-to-earnings ratio of 24.33, a PEG ratio of 3.34 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.73 by $0.42. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period last year, the business earned $4.90 earnings per share. Amgen’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts predict that Amgen Inc. will post 22.16 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results: Amgen reported EPS of $5.15 vs. consensus ~$4.74 and revenue of $8.62B vs. ~$8.58B — beats on both lines and sales rose ~4%, supporting the near‑term earnings story. Amgen’s (NASDAQ:AMGN) Q1 CY2026 sales top estimates
• Positive Sentiment: Mgmt commentary/slides: Management framed 2026 as a “springboard” year and highlighted six growth drivers; investors may take this as confidence in product mix and pipeline execution. Amgen (AMGN) Q1 2026 Earnings Transcript
• Positive Sentiment: Pipeline progress: Amgen is advancing a broader development program for weight‑loss candidate MariTide and submitted a label update to the FDA for an autoimmune drug — signs of R&D activity that could drive medium‑term growth. Amgen sales rise 4% in first quarter, submits label update to FDA on autoimmune drug
• Neutral Sentiment: Guidance: FY‑2026 EPS guidance set to 21.700–23.100 (consensus ~22.29); revenue guidance $37.1B–$38.5B (consensus ~37.8B) — range leaves room for beats or misses, which could sustain volatility as analysts model the year. Amgen Q1 press release and slide deck
• Neutral Sentiment: Analyst sentiment: Wall Street remains moderately optimistic on targets but Amgen has underperformed the market over the past year — analysts will reassess models after the quarter. What Are Wall Street Analysts’ Target Price for Amgen Stock?
• Negative Sentiment: Tavneos regulatory risk: An FDA advisory panel raised efficacy/data concerns for Tavneos and there have been reports of a proposed U.S. withdrawal — this is a material downside catalyst for a rare‑disease franchise and could pressure sentiment until resolved. Amgen faces U.S. withdrawal of rare disorder therapy Tavneos

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.